619 results about "Cardiomyopathy" patented technology

The present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect, and more particularly, to a RF ablation catheter for septal reduction therapy that is for performing RF ablation, in which RF energy is applied to an interventricular septum, for septal reduction therapy such as therapy for hypertrophic cardiomyopathy, which is a disease in which an interventricular septum of the left ventricle of the heart of the animal or human body thickens, therapy that requires reduction of an interventricular septum, or therapy for ventricular tachycardia. Also, the present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect that is for preventing carbonization of a tissue of the body (interventricular septum) around an electrode.An exemplary embodiment of the present disclosure provides a RF catheter for septal reduction therapy, the RF catheter including: an intra-septal part in which a tapered tip which becomes thinner toward an end thereof is formed at an end of a distal part and one or more electrodes are formed at positions on an outer circumferential surface that are adjacent to the tip; and a body part which is made of a soft material and has a guidewire lumen which passes through the intra-septal part from an inlet formed at the center of the end of the tip and has an outlet formed in a side surface, a coolant inlet lumen which is connected from a proximal part to an inner portion of the intra-septal part to allow a coolant to be injected from the outside and which has an open end, and a coolant outlet lumen which communicates with the coolant inlet lumen and has an exit formed in a side surface, wherein the guidewire lumen and the coolant inlet lumen do not communicate with each other and are partitioned from each other.

The present invention relates to a radiofrequency electrode ablation catheter for ventricular septal therapy with a cooling function, which is used for performing radiofrequency electrode ablation and has a cooling function for preventing carbonization of body (ventricular septum) tissue around the electrode, wherein radiofrequency energy is applied to the ventricular septum during radiofrequency electrode ablation to perform ventricular septal therapy (e.g., therapy for hypertrophic cardiomyopathy, a disease in which the left ventricular septum of the heart of an animal or human body becomes thickened, therapy requiring reduction of the ventricular septum, or ventricular tachycardia, etc.). The radiofrequency catheter for ventricular septal therapy according to a preferred embodiment of the present invention includes a septal insertion portion and a body portion.

This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting feline NT-proBNP protein and its applications. The monoclonal antibody combination of the present invention comprises monoclonal antibodies 3A6 and 5H5. These two antibodies possess unique heavy and light chain variable region complementarity-determining regions, respectively, and their amino acid sequences have been fully defined (SEQ ID NOs. 1-12). This antibody combination can specifically recognize and efficiently bind to feline NT-proBNP protein, making it suitable for the development of a highly sensitive and specific diagnostic tool for feline cardiomyopathy. By constructing a double-antibody sandwich ELISA assay system, the minimum detection limit can reach 100 pg / mL, and it exhibits excellent specificity and stability.

The invention belongs to the technical field of medicines, particularly relates to application of deaminotyrosine in preparation of a medicine for treating cardiomyopathy caused by anthracycline medicines, discovers that DAT can relieve cardiotoxicity caused by DOX to a great extent, and can provide a new thought for recovery of patients after chemotherapy and expansion of clinical application of DOX.

The invention relates to a hypertrophic obstructive cardiomyopathy virtual resection operation curative effect evaluation method based on individualized computational fluid mechanics, which can give visual postoperative hemodynamic indexes, predict postoperative curative effects, find an optimal resection scheme and realize preoperative accurate intelligent evaluation. Comprising the following steps of: acquiring coronary artery enhanced computed tomography image data, acquiring a coronary artery enhanced computed tomography image of a patient, and outputting and storing the coronary artery enhanced computed tomography image in a DICOM (Digital Imaging and Communications in Medicine) format; preprocessing image data, and segmenting and reconstructing a left ventricle-outflow tract structure three-dimensional model; setting a virtual excision scheme at the fleshy part; constructing a surgical resection model, and importing the model into finite element analysis software for solving; and the virtual postoperative curative effect is visualized. Verification and curative effect prediction of a patient excision scheme can be realized, and the operation success rate of a hypertrophic obstructive cardiomyopathy patient is improved.

The invention discloses application of fisetin or a salt thereof in medicine preparation, the compound is used for treating or preventing obesity cardiomyopathy, preferably heart diseases caused by hyperlipidemia, but is not limited to the inducer, and specifically, the medicine can inhibit or improve various obesity cardiomyopathy.

The invention discloses a diabetic cardiomyopathy clinical prediction model, an establishment method and application thereof. The method includes the steps that clinical data of type II diabetes patients meeting the containing and discharging standard are collected based on public health data and processed, a random forest RF prediction model is established, the random forest RF prediction model is trained and evaluated to finally establish the random forest RF prediction model, the model accuracy is 0.889, the sensitivity is 0.896, the specificity is 0.880, and the recall rate is 0.896. The model has higher prediction accuracy and robustness, and can be used for an intuitive and convenient webpage calculator for early diagnosis of the diabetic cardiomyopathy, so that a clinician can easily predict the risk of the diabetic cardiomyopathy, resources are allocated according to a prediction result, and waste of medical resources is reduced.

An RNAi agent and composition for inhibiting the expression of transthyretin (TTR), which can be used for treating and / or preventing ATTR-related diseases comprising ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis diseases, and leptomeningeal / central nervous system amyloidosis diseases.

The invention provides a dilated cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology.The dilated cardiomyopathy zebrafish model is constructed by overexpressing miR-16-5p in myocardial cells of zebrafish, and the sequence of miR-16-5p is shown as SEQ ID NO.1; the invention further provides a construction method of the dilated cardiomyopathy zebra fish model. The invention constructs the dilated cardiomyopathy zebrafish model of overexpression miR-16-5p in myocardial cells for the first time, and the dilated cardiomyopathy zebrafish model can be used for screening drugs for resisting dilated cardiomyopathy.

Disclosed in the present invention is a use of alisol-B23-acetate (AB23a) in the preparation of a drug for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. The present invention provides for the first time a use of AB23a in the prevention or treatment of hypertrophic cardiomyopathy. According to the present invention, use of AB23a in direct in vitro treatment of cardiomyocytes derived from directed differentiation of human embryonic stem cells revealed that AB23a-based in-vitro treatment can significantly inhibit hypertrophic phenotypes of the human embryonic stem cells-cardiomyocytes; using an AB23a-containing feed to feed mice with hereditary hypertrophic cardiomyopathy caused by a gene mutation revealed that AB23a prominently relieves pathological myocardial hypertrophy of the mice and improves the cardiac function; AB23a can be used for preparing a drug for resisting hereditary hypertrophic cardiomyopathy, offering a novel way and means for treating hypertrophic cardiomyopathy; and AB23a is the main medicinal ingredient in the traditional Chinese medicinal herb-Rhizoma Alismatis, is safe to organisms, and has good clinical application prospects.

A method for remodeling a heart chamber. A catheter system can be used to deliver implants to the heart chamber. A user can use a handle to adjust the tension of sutures between the implants to adjust the size of the heart chamber. The heart chamber can be remodeled at specific dimensions to address cardiomyopathy in a patient-specific manner.

The present disclosure provides exemplary sequences and compositions that can be used to active immunization of animals to aid in the prevention of cardiomyopathy syndrome (CMS) caused by Piscine Myocarditis Virus (PMCV). Vaccines and kits comprising the sequences and compositions are also provided, as well as methods of administering the vaccine to non-human animals.

The invention relates to the technical field of pharmaceutical preparations, in particular to a rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition and a preparation method thereof, and the rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition comprises a quick release layer, a slow release layer and an osmotic pump structural design. According to the application, staged or constant-rate release of rapamycin within 168 hours is realized through a multi-phase release technology or an osmotic pump technology, and the problems that an existing preparation is large in blood concentration fluctuation, high in administration frequency and low in bioavailability are solved. The composition is suitable for treating hypertrophic cardiomyopathy of cats, significantly improves cardiac functions and reduces side effects and risks, is administered once a week, and is convenient to use. The invention further provides a storage method, and the product stability is ensured. The technical scheme has remarkable clinical advantages and application prospects.

The invention belongs to the field of biological medicine, and relates to siRNA for inhibiting PLN gene expression and a conjugate, the siRNA comprises a positive-sense strand and an antisense strand, the positive-sense strand comprises a nucleotide sequence I, and the antisense strand comprises a nucleotide sequence II; each nucleotide in the nucleotide sequence I and the nucleotide sequence II is modified or unmodified nucleotide; the nucleotide sequence I and the nucleotide sequence II are at least partially reversely complementary to form a double-stranded region; the nucleotide sequence I is basically consistent with a first section of nucleotide sequence, and the first section of nucleotide sequence is a section of nucleotide sequence with the length of at least 19 nucleotides in mRNA expressed by the PLN gene. The siRNA and the conjugate and the pharmaceutical composition thereof disclosed by the invention can effectively prevent and / or treat diseases associated with PLN expression, such as heart failure, cardiomyopathy, arrhythmia and the like, and have a good patent medicine prospect.

The invention discloses a construction method of a sepsis cardiomyopathy diagnosis model and a diagnosis system, and relates to the technical field of biomedicine, and the method comprises the following steps: carrying out multi-mode ultrasonic data dynamic collection and clinical data collection on a sepsis patient; according to the multi-mode ultrasonic data, evaluating the overall and local diastolic and contraction functions of the left ventricle and the right ventricle of the heart of the patient with sepsis cardiomyopathy, and performing preliminary diagnosis of sepsis cardiomyopathy in combination with clinical data; the method comprises the following steps: dividing multi-modal ultrasonic data of a sepsis patient into a training set and a verification set by using an Rcaret packet, and carrying out minimum absolute contraction and LASSO regression analysis on the training set to determine a preliminary prediction factor; carrying out logistic regression analysis on the preliminary prediction factor, and determining an independent prediction factor; the independent predictive factors are translated in nomoscore through an rms packet to obtain a column diagram, the independent predictive factors are visually presented according to the weights of the independent predictive factors, and the probability of occurrence of sepsis cardiomyopathy is measured. According to the invention, comprehensive and dynamic quantitative evaluation of the cardiac function of the patient is realized based on the multi-modal ultrasonic parameters.

Genome sequencing identified a new gene associated with a cardiac arrhythmic disease, TAXI -binding protein 3. From cell line models and a conditional knock-out mouse models of the gene deletion, it was found that a specific molecule, transient receptor potential vanilloid 4 (TRPV4), is up-regulated and is associated with calcium mediated arrhythmic depolarizations.

The invention provides a hypertrophic cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology, the hypertrophic cardiomyopathy zebrafish model is constructed by overexpressing miR-29a in myocardial cells of zebrafish, and the sequence of the miR-29a is shown as SEQ ID NO.1; the invention further provides a construction method of the hypertrophic cardiomyopathy zebra fish model. The hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) with overexpression of miR-29a in myocardial cells is constructed for the first time, and the hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) can be used for screening drugs for resisting hypertrophic cardiomyopathy.

The invention discloses a high-throughput screening method and a high-throughput screening system for a KLHL24 ubiquitin ligase inhibitor, which are high in stability and good in repeatability and are beneficial to efficient screening of the KLHL24 ubiquitin ligase inhibitor and development of related drugs. Based on the method, some KLHL24 ubiquitin ligase inhibitors are screened out, can be effectively used for treating diseases related to KLHL24, especially diseases caused by KLHL24 mutation, such as hereditary bullous epidermis, dilated cardiomyopathy, alopecia and atrophic scar, and have very good application prospects. In view of the function of KLHL24 in the aspect of skin and hair regeneration, the inhibitor also has a relatively good application prospect in the aspect of maintaining normal hair.

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.

The invention provides an ablation needle assembly and an ablation system. The ablation needle assembly comprises a hollow outer sleeve and an ablation needle, the outer sleeve is movably arranged outside an electrode needle body of the ablation needle in a sleeving mode and is detachably and rotatably connected with an ablation handle, so that after ablation operation is completed, the ablation needle and the outer sleeve can be detached, the outer sleeve is still left in tissue, a channel is provided for other operations such as biopsy, and the ablation needle assembly is simple in structure and convenient to use. Repeated puncture is avoided, damage to tissue is reduced, and biopsy operation can be more convenient and efficient. Furthermore, the ablation handle is rotationally connected with the outer sleeve, so that the ablation handle can drive the electrode needle main body to rotate relative to the outer sleeve when rotating relative to the outer sleeve, that is, the outer sleeve and the electrode needle main body are not of an integrated structure, and when the ablation needle needs to be rotated, the outer sleeve can be kept not rotating, so that damage to tissues is reduced; and the rotation resistance is small. Therefore, the ablation needle assembly and the ablation system are particularly suitable for radiofrequency ablation treatment of hypertrophic cardiomyopathy.

The embodiment of the invention relates to a processing method and device for a hypertrophic cardiomyopathy risk prediction model. The method comprises the following steps: constructing the hypertrophic cardiomyopathy risk prediction model; constructing a generalized crowd model data set as a first data set, and constructing a specified crowd model data set as a second data set based on the specified crowd characteristics; performing pre-training on the model based on the first data set, and then performing fine tuning on the model based on the second data set; after fine tuning is finished, inputting a tested person myocardial strain parameter set meeting the characteristics of the specified crowd into the model for prediction, and feeding back a prediction result to a user. According to the invention, prediction accuracy and prediction stability can be improved.

The invention discloses a hypertrophic cardiomyopathy (HCM) preoperative planning and operation effect evaluation method based on accurate digital labeling. The method comprises the following steps: performing digital labeling on the thickness of each wall of a left ventricle of a preoperative heart 3D digital model; according to the digital labeling result of the preoperative heart 3D digital model and the normal value of the thickness of the left ventricular wall, a doctor manually depicts the predicted resection range and confirms the predicted retention thickness; measuring the predicted resection volume, the predicted resection area and the left ventricular end diastolic volume after the predicted resection volume is resected; digitally marking the thickness of each wall of the left ventricle of the postoperative heart 3D digital model, and measuring the volume of the corresponding left ventricle in the end diastole; and taking the predicted resection range, the predicted retention thickness, the predicted resection volume, the predicted resection area and the predicted volume as first evaluation data, taking corresponding parameters of the postoperative heart 3D digital model as second evaluation data, and generating an operation evaluation result according to the conformity of the first evaluation data and the second evaluation data.

The present disclosure relates, in part, to gene replacement to treat cardiomyopathy. In embodiments, the invention provides compositions and methods of use to treat ALPK3 cardiomyopathy. In embodiments, invention provides a composition comprising a nucleic acid encoding all or a portion of an ALPK3 protein.

The invention discloses a pyrimidinedione derivative as well as a preparation method and application thereof. Molecules of the pyrimidinedione derivative have better myosin inhibitory activity, also have antioxidant effects of DPPH and / or MDA and the like and anti-ferroptosis activity, and can be applied to treatment / prevention of heart myosin, anti-oxidative stress and anti-ferroptosis mechanism related diseases. The diseases or symptoms mainly comprise hypertrophic cardiomyopathy, diastolic heart failure, left ventricular hypertrophy, heart diseases with pathophysiological characteristics related to the hypertrophic cardiomyopathy, or other disease states and conditions which are obvious to those skilled in the art, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof, and a pharmaceutical composition containing the same.

The invention relates to the technical field of biological medicines, and discloses application of AVEN as a target spot in preparation of a medicine for treating adriamycin cardiomyopathy. Wherein the AVEN is taken as the target spot, the AVEN is overexpressed by targeting cardiac myocardial cells, and further, the overexpressed AVEN by targeting cardiac myocardial cells comprises the step of improving the expression of the AVEN gene in the cardiac myocardial cells by adopting a substance capable of activating or up-regulating the expression of the AVEN in a targeting manner. It is found for the first time that specific overexpression of AVEN in myocardial cells can inhibit ferroptosis of myocardial cells, relieve myocardial fibrosis and myocardial atrophy, significantly improve adriamycin-induced cardiac dysfunction, and improve life quality and long-term prognosis of patients.

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

The present disclosure provides methods, compounds, compositions / formulations / medicaments and related uses for treating, preventing, delaying the progression of or delaying the onset of cardiomyopathy, such as hypertrophic cardiomyopathy, in a mammalian subject, such as a subject diagnosed with, or suspected or having, Friedreich's ataxia. In some embodiments, administration of the disclosed compounds to the subject may result in one or more of the following in the subject: (i) an increase in survival, (ii) reduction in iron deposits in cardiomyocytes, (iii) improvement and / or normalization of mitochondria size in cardiomyocytes; (iv) reduction in cardiac fibrosis, and (v) reverse remodeling of the subject's heart.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.